+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Investigation Report on China's Glimepiride Market, 2018-2022

  • PDF Icon

    Report

  • 30 Pages
  • November 2018
  • Region: China
  • China Research & Intelligence
  • ID: 4702512
Glimepiride is a third-generation sulfonylurea insulin secretagogue. Sanofi’s brand-name drug (trade name: Amaryl) have been marketed in many countries after it was approved by the FDA (U.S. Food and Drug Administration) on Nov. 30, 1995. Glimepiride is the sulfonylurea hypoglycemic agent that has best clinical effectiveness as well as the first sulfonylurea approved by the FDA to be used together with insulin. It does much better in sensitizing and simulating insulin than other sulfonylureas. For type 2 diabetic patients with insulin resistance (reduced glucose utilization in peripheral tissues), Glimepiride reduces blood glucose by sensitizing and simulating insulin. For type 2 diabetic patients with insulin secretion dysfunction, Glimepiride reduces blood glucose by stimulating insulin secretion.

According to the author, with the development of China's economy, the rise of urbanization level, and the aging of population, the life style of Chinese people is changing, which increases the obese population and the incidence of diabetes in China. It is estimated that the number of type 2 diabetic patients in China had surpassed 1 million by the end of 2017, and is growing by 1.5 million to 2 million every year. The growing number of diabetics in China promotes the growth of the antidiabetic drug market.

According to the author, generic products have sprung up one after another since 2004 when Sanofi (Beijing) Pharmaceutical Co., Ltd. launched Amaryl in China. In 2017, the market size of Glimepiride in China was about CNY 302 million. There are over 10 Glimepiride manufacturers in China. The major market players include Sanofi (Beijing) Pharmaceutical Co., Ltd., Jiangsu Wanbang Biopharmaceuticals Co., Ltd., CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd., and Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. By sales value, in 2017, Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Amaryl captured more than 80% share of China’s Glimepiride market.

It is expected that as the number of diabetics continues to grow, China's Glimepiride market will have huge growth potential in the next few years.

Topics Covered:

  • Situation of diabetes in China
  • Sales of Glimepiride in China
  • Competition on China's Glimepiride market
  • Prices of Glimepiride in China
  • Forecasts on China's Glimepiride market from 2018 to 2022

Table of Contents

1. Relevant Concepts of Glimepiride
1.1 Indications for Glimepiride
1.2 Development of Glimepiride in China
1.3 Governmental Approval of Glimepiride in China
2. Sales of Glimepiride in China, 2013-2017
2.1 Sales Value of Glimepiride
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Glimepiride
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Glimepiride by Dosage Form in China, 2013-2017
2.3.1 Tablets
2.3.2 Capsules
2.3.3 Pills
3. Analysis on Major Glimepiride Manufacturers in China, 2013-2017
3.1 Analysis on Market Share of Major Glimepiride Manufacturers
3.1.1 Market Share by Sales Value
3.1.2 Market Share by Sales Volume
3.2 Sanofi (Beijing) Pharmaceutical Co., Ltd.
3.2.1 Enterprise Profile
3.2.2 Sales of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in China
3.3 Jiangsu Wanbang Biopharmaceuticals Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in China
3.4 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
3.5 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.
3.6 Sanofi
4. Prices of Glimepiride in China, 2017-2018
4.1 Sanofi (Beijing) Pharmaceutical Co., Ltd. (Amaryl)
4.2 Jiangsu Wanbang Biopharmaceuticals Co., Ltd. (Wansuping)
4.3 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (Linmeixin)
4.4 Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd. (Yousu)
4.5 Sanofi (Amaryl)
5. Prospect of China's Glimepiride Market, 2018-2022
5.1 Forecast on Market Size
5.2 Forecast on Market Trend
List of Charts
Chart Sales of Glimepiride in China, 2013-2017
Chart Sales Value of Glimepiride in Parts of China, 2013-2017
Chart Sales Volume of Glimepiride in China, 2013-2017
Chart Sales Volume of Glimepiride in Parts of China, 2013-2017
Chart Sales Value of Glimepiride Tablets in China, 2013-2017
Chart Sales Volume of Glimepiride Tablets in China, 2013-2017
Chart Sales Value of Glimepiride Capsules in China, 2013-2017
Chart Sales Value of Glimepiride Pills in China, 2013-2017
Chart Sales Volume of Glimepiride Pills in China, 2013-2017
Chart Market Share of Top 5 Glimepiride Manufacturers by Sales Value in China, 2013-2017
Chart Market Share of Top 5 Glimepiride Manufacturers by Sales Volume in China, 2013-2017
Chart Sales Value of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride, 2013-2017
Chart Sales Volume of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride, 2013-2017
Chart Sales Value of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride, 2013-2017
Chart Sales Value of CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Glimepiride, 2013-2017
Chart Sales Value of Sanofi's Glimepiride, 2013-2017
Chart Prices of Sanofi (Beijing) Pharmaceutical Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
Chart Prices of Jiangsu Wanbang Biopharmaceuticals Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
Chart Prices of CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
Chart Prices of Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co., Ltd.'s Glimepiride in Parts of China, 2017-2018
Chart Prices of Sanofi's Glimepiride in Parts of China, 2017-2018

Companies Mentioned

  • CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.
  • Jiangsu Wanbang Biopharmaceuticals Co. Ltd.
  • Sanofi (Beijing) Pharmaceutical Co. Ltd.
  • Yangtze River Pharmaceutical Group Guangzhou Hairui Pharmaceutical Co. Ltd

Methodology

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...